Francesco DeRubertis
Director/Board Member at Palladio Biosciences, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Condella | M | 70 |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | - |
| Alex Martin Martin | M | 56 |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | 5 years |
| Michèle Ollier | M | 66 |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 3 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Francesco DeRubertis
- Personal Network
